| HealthPartners | Ocular anti-VEGF medications | 2026-01-01 |
| HealthPartners | Olipudase alfa-rpcp (Xenpozyme™) | 2026-01-01 |
| HealthPartners | Oncology - asparaginase erwinia chryanthemi | 2026-01-01 |
| HealthPartners | Oncology - belantamab (Blenrep®) – Minnesota Health | 2026-01-01 |
| HealthPartners | Oncology - bevacizumab (Avastin®, Mvasi™, Zirabev® | 2026-01-01 |
| HealthPartners | Oncology - bevacizumab (Avastin®, Mvasi™, | 2026-01-01 |
| HealthPartners | Oncology - blinatumomab (Blincyto™) | 2026-01-01 |
| HealthPartners | Oncology - brentuximab vedotin (Adcetris®) – | 2026-01-01 |
| HealthPartners | Oncology - cemiplimab-rwlc (Libtayo®) – Minnesota | 2026-01-01 |
| HealthPartners | Oncology - chimeric antigen receptor/genetically | 2026-01-01 |